FDA Sidelines Chief Spokesperson As It Grapples With Fallout From COVID-19 Plasma Authorization

Emily Miller, who joined FDA a few days before its controversial roll out of emergency use authorization for convalescent plasma, remains at the agency. Situation shows importance of sticking to science-based decisions, former FDA officials say.

Clouds-Lightning-Storm_1200x675
FDA dealing with political firestorm after COVID-19 convalescent plasma authorization • Source: Shutterstock

The political firestorm engulfing the US Food and Drug Administration continues, with its chief spokesperson, Emily Miller, being sidelined following fierce criticism of the way the agency handled an emergency use authorization for COVID-19 convalescent plasma. The situation shows the consequences of FDA straying from its strictly science-based approach and the turmoil going on within the agency as it deals with pressures inside and outside the Trump Administration.

The sidelining of Miller, first reported by the New York Times, suggests she was being held accountable, at least in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership